Dicot AB
The answer first
Does Dicot beat the market?
No, Dicot has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 28% of Nordic stocks
- Quality75
- Value5
- Trend41
No. 110 of 195 in healthcare
Max for seven days
Follow Dicot with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Dicot
Your first answer is free, no account needed.
Do you own Dicot, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Dicot and a few more. Free, no card.
Super Stock+45.9%In short
- Dicot has fallen 41.4% over the past year, including dividends.
- Overall, Dicot ranks better than 28% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 89.9%. The price is 95.4% below its peak now.
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 28% of Nordic stocks.
No. 110 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 71 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity–
- Asset turnoverSales divided by everything the company owns0.00
- Return on equityProfit divided by equity−32.7%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 160 of 197 in healthcareTypical in healthcare: 21Typical in the Nordics: 50
- P/BPrice divided by equity3.1
- P/SPrice divided by sales–
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Medium The share price has moved about like most stocks over the last year.
No. 86 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months+0.5%
- 6 months+0.5%
- 9 months−32.9%
- 12 months−41.4%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
About Dicot
Dicot AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 4 employees.
Dicot Pharma AB (publ) engages in the development of pharmaceutical products in Sweden. It develops LIB-01 that is in Phase 2a clinical trial for the treatment of erectile dysfunction and under medical discovery for treating premature ejaculation. The company was formerly known as Dicot AB (publ) and changed its name to Dicot Pharma AB (publ) in May 2024. Dicot Pharma AB (publ) was incorporated in 2015 and is based in Uppsala, Sweden.


See the full analysis of Dicot.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card